| Literature DB >> 23894661 |
Rutger Matthes1, Claudia Bender, Rabea Schlüter, Ina Koban, René Bussiahn, Stephan Reuter, Jürgen Lademann, Klaus-Dieter Weltmann, Axel Kramer.
Abstract
The treatment of infected wounds is one possible therapeutic aspect of plasma medicine. Chronic wounds are often associated with microbial biofilms which limit the efficacy of antiseptics. The present study investigates two different surface barrier discharges with air plasma to compare their efficacy against microbial biofilms with chlorhexidine digluconate solution (CHX) as representative of an important antibiofilm antiseptic. Pseudomonas aeruginosa SG81 and Staphylococcus epidermidis RP62A were cultivated on polycarbonate discs. The biofilms were treated for 30, 60, 150, 300 or 600 s with plasma or for 600 s with 0.1% CHX, respectively. After treatment, biofilms were dispensed by ultrasound and the antimicrobial effects were determined as difference in the number of the colony forming units by microbial culture. A high antimicrobial efficacy on biofilms of both plasma sources in comparison to CHX treatment was shown. The efficacy differs between the used strains and plasma sources. For illustration, the biofilms were examined under a scanning electron microscope before and after treatment. Additionally, cytotoxicity was determined by the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay with L929 mouse fibroblast cell line. The cell toxicity of the used plasma limits its applicability on human tissue to maximally 150 s. The emitted UV irradiance was measured to estimate whether UV could limit the application on human tissue at the given parameters. It was found that the UV emission is negligibly low. In conclusion, the results support the assumption that air plasma could be an option for therapy of chronic wounds.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23894661 PMCID: PMC3722131 DOI: 10.1371/journal.pone.0070462
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Operational parameters of SBD-A and SBD-B.
| SBD-A | SBD-B | ||
| properties | |||
|
| 13 | 8 | |
|
| 20 | 30 | |
|
| burst (2 pulse/ms) | burst (30 pulse/ms) | |
| = 800 pulse in 400 ms | = 7500 pulse in 250 ms | ||
|
| 400 ms on, 1200 ms off | 250 ms on, 750 ms off | |
|
| 0.6 | 0.44 | |
|
| 0.03 | 0.18 | |
|
| 1.8 | 10.88 | |
|
| 10 | 18 | |
|
| circular | rectangular | |
|
| 0 | 0.5 | |
Figure 1Experimental setup of the SBD-A plasma source.
A: Electrode and discs with biofilms on plastic flat grate. B: Configuration of the electrode in action mode. C: Schematic representation of the experimental setup of SBD-A.
Figure 2Experimental setup of the SBD-B plasma source.
A: Overview of the experimental setup. B: Near focus of the electrode in action mode above the discs with biofilms. C: Schematic representation of the experimental setup of SBD-B in cross section.
Antiseptic treatment of Pseudomonas aeruginosa SG81 biofilms.
| SBD-A | SBD-B | ||||||||
| 95% CI limits | 95% CI limits | ||||||||
| treatment | n | CRF ± SD | lower | upper | n | CRF ± SD | lower | upper | p |
|
| 20 |
| 1.25 | 1.63 | 26 |
| 0.92 | 1.40 | 0.0037 |
|
| 24 |
| 1.48 | 2.07 | 20 |
| 1.13 | 1.51 | 0.0267 |
|
| 22 |
| 2.26 | 2.94 | 20 |
| 1.76 | 2.37 | 0.0136 |
|
| 23 |
| 3.88 | 5.77 | 20 |
| 2.53 | 3.43 | 0.0050 |
|
| 16 |
| 6.48 | 7.73 | 12 |
| 2.85 | 4.77 | 0.0001 |
| p | 0.0001 | 0.0001 | 0.0001 | ||||||
|
| 35 |
| 1.56 | 1.88 | |||||
|
| 38 |
| −0.05 | 0.05 | |||||
| p | 0.0001 | 0.0001 | 0.0001 | ||||||
The analytical results by the Number of samples (n), Colony reduction factor (CRF) in log10 (CFU/cm2) ± Standard Deviation (SD), lower and upper 95% confidence limits (CI) after exposure to air plasma for 30–600 s treatment time respectively and 0.1% CHX after 600 s exposure time and untreated control of Pseudomonas aeruginosa SG81 biofilms [p-values of omnibus tests (Kruskal-Wallis) and two-sample tests (Whitney U); statistical significance: α = 0.05].
significantly different from CHX.
significantly different from the respective treatment time of Staphylococcus epidermidis RP62A.
Antiseptic treatment of Staphylococcus epidermidis RP62A biofilms.
| SBD-A | SBD-B | ||||||||
| 95% CI limits | 95% CI limits | ||||||||
| treatment | n | CRF ± SD | lower | upper | n | CRF ± SD | lower | upper | p |
|
| 20 |
| 0.36 | 0.97 | 12 |
| 0.28 | 0.85 | 0.8763 |
|
| 22 |
| 1.09 | 2.01 | 20 |
| 1.05 | 1.42 | 0.5795 |
|
| 22 |
| 1.79 | 2.85 | 20 |
| 1.19 | 1.71 | 0.0219 |
|
| 22 |
| 2.20 | 3.33 | 20 |
| 1.77 | 2.31 | 0.0698 |
|
| 16 |
| 2.92 | 3.85 | 12 |
| 2.07 | 3.31 | 0.0459 |
| p | 0.0001 | 0.0001 | 0.0001 | ||||||
|
| 32 |
| 0.88 | 1.41 | |||||
|
| 30 |
| −0.11 | 0.11 | |||||
| p | 0.0001 | 0.0001 | 0.0001 | ||||||
The analytical results by the Number of samples (n), Colony reduction factor (CRF) in log10 (CFU/cm2) ± Standard Deviation (SD), lower and upper 95% confidence limits (CI) after exposure to air plasma for 30–600 s treatment time and 0.1% CHX after 600 s exposure time and untreated control of Staphylococcus epidermidis RP62A biofilms [p-values of omnibus tests (Kruskal-Wallis) and two-sample tests (Whitney U); statistical significance: α = 0.05].
significantly different from CHX.
significantly different from the respective treatment time of Pseudomonas aeruginosa SG81.
Figure 3Scanning electron micrographs of untreated and air plasma treated biofilms on polycarbonate discs.
A) untreated biofilm of Pseudomonas aeruginosa SG81 (5000-fold), B) untreated biofilm of Staphylococcus epidermidis RP62A (5000-fold), C) Pseudomonas aeruginosa SG81 biofilms after 300 s of air plasma treatment by SBD-A (2000-fold) and D) by SBD-B (1500-fold) as well as E) Staphylococcus epidermidis RP62A biofilms after 300 s of air plasma treatment by SBD-A (1000-fold) and F) by SBD-B (5000-fold).
Figure 4Scanning electron micrographs of cell morphology damaged biofilm bacteria on polycarbonate discs after 300 s of air plasma treatment with A) Pseudomonas aeruginosa SG81 by SBD-B (7000-fold) and B) Staphylococcus epidermidis RP62A by SBD-A (10000-fold).
Figure 5Spectrometric graph of irradiance by SBD-B generated air plasma within 300 s of exposure time between 200 and 400 nm.
Cytotoxicity of air plasma by SBD-A and SBD-B on L929 cell line (mouse fibroblasts).
| SBD-A | SBD-B | |||||||||
| treatment | n | mean ± SD | ratio to control (%) | n | mean ± SD | ratio to control (%) | ||||
|
| 3 | 0.090 ± 0.022 |
| 2 | 0.094 ± 0.004 |
| ||||
|
| 4 | 0.096 ± 0.005 |
| 4 | 0.075 ± 0.004 |
| ||||
|
| 4 | 0.075 ± 0.022 |
| 4 | 0.085 ± 0.014 |
| ||||
|
| 4 | 0.036 ± 0.024 |
| 4 | 0.044 ± 0.032 |
| ||||
|
| 4 | 0.004 ± 0.003 |
| 4 | 0.043 ± 0.028 |
| ||||
|
| 2 | 0.088 ± 0.010 |
| |||||||
|
| 4 | 0.102 ± 0.011 |
Measured values of MTT-Assay after 30–600 s treatment time of air plasma by SBD-A and SBD-B with the Number of samples (n), mean, standard deviation (SD), and the cell viability as ratio in comparison to the control in percent.
Cytotoxicity of 0.1% chlorhexidine digluconate solution on L929 cell line (mouse fibroblasts).
| CHX (0.1%) | |||||
| treatment | n | mean ± SD | ratio to control (%) | ||
|
| 3 | 0.046 ± 0.029 |
| ||
|
| 3 | 0.021 ± 0.017 |
| ||
|
| 3 | 0.069 ± 0.013 |
| ||
|
| 3 | 0.016 ± 0.011 |
| ||
|
| 3 | 0.007 ± 0.002 |
| ||
|
| 6 | 0.267 ± 0.076 | |||
Measured values of MTT-Assay after 30–600 s treatment time with 0.1% of chlorhexidine dicluconate solution (in culture media) with the Number of samples (n), mean, standard deviation (SD), and the cell viability as ratio in comparison to the control in percent.